3/8/2012 | CVHYPF | Adventrx files $150 million stock, preferreds, debt shelf registration
|
11/14/2011 | PP | Adventrx Pharmaceuticals prices $17 million public units sale at $0.80
|
11/10/2011 | PP | Adventrx Pharmaceuticals plans public sale of common stock, warrants
|
1/7/2011 | PP | Adventrx negotiates $22.51 million registered direct offering of units
|
5/3/2010 | PP | Market Commentary: Sterling Financial heralds $555 million offering; Adventrx to sell convertible preferred stock
|
3/25/2010 | CVHYPF | Adventrx files $150 million shelf for stock, preferreds and debt
|
1/4/2010 | PP | Market Commentary: Adventrx seeks up to $19 million; La Cortez seals $2.5 million issue; Levon settles unit sale
|
1/4/2010 | PP | New Issue: Adventrx orchestrates $19 million direct sale of convertible preferreds
|
10/9/2009 | PP | Market Commentary: Sea Dragon seeks C$10 million; Adventrx wraps placement; UraniumSA plans two-tranche deal
|
10/6/2009 | PP | New Issue: Adventrx Pharmaceuticals details $11.28 million preferreds offering
|
10/6/2009 | PP | Market Commentary: Canyon to finance up to C$50 million; Adventrx plans convertible preferreds; Petro sells units
|
10/5/2009 | PP | New Issue: Adventrx Pharmaceuticals arranges $11.28 million preferred direct sale
|
8/5/2009 | PP | New Issue: Adventrx arranges $900,000 direct offering of 5% convertible preferreds
|
7/24/2009 | CV | Adventrx to offer up to $10 million convertible preferreds to fund product development
|
6/29/2009 | PP | New Issue: Adventrx plans $1.36 million direct offering of convertible preferreds
|
6/8/2009 | PP | New Issue: Adventrx to issue $1.99 million convertible preferreds, warrants in private placement
|
5/21/2009 | CV | Adventrx files $25 million shelf registration covering debt, warrants
|
11/6/2006 | BT | Market Commentary: Abbott Labs stock off on Kos Pharmaceuticals acquisition news; VaxGen may lose government contract
|
11/6/2006 | PP | Market Commentary: Neurochem gears up to wrap $40 million convertibles; Pacific Energy reprices
|
11/3/2006 | BT | Market Commentary: Celgene sells $1 billion of stock; Hollis-Eden up amid Q3 net loss; Spectrum higher following earnings
|
11/3/2006 | PP | Market Commentary: Adventrx to seal $40 million direct sale; Avanir brings $15 million
|
11/3/2006 | BTPP | New Issue: Adventrx secures $40 million from direct placement of stock
|
9/25/2006 | BT | Adventrx completes enrollment in CoFactor colorectal cancer trial
|
9/18/2006 | BT | Adventrx: CoFactor, Uftoral had greater growth inhibition of colorectal tumors
|
9/8/2006 | BT | Adventrx CFO resigns; new president takes the helm
|
7/12/2006 | BT | Adventrx Pharmaceuticals to redeem warrants
|
6/29/2006 | BT | Adventrx: Supplemental results encouraging for CoFactor in colorectal cancer trial
|
6/28/2006 | BT | Adventrx begins phase 3 pivotal trial of CoFactor in metastatic colorectal cancer
|
6/26/2006 | BT | Data Safety Monitoring Board approves continuation of Adventrx phase 2b CoFactor trial in cancer
|
6/22/2006 | BT | Adventrx says studies show broad antiviral activity for Thiovir
|
6/5/2006 | BT | Adventrx says phase 2 CoFactor trial exceeds primary endpoint expectations
|
6/5/2006 | BT | Adventrx maintained at perform rating by RBC
|
5/24/2006 | BT | Market Commentary: Sirna, Minrad, AngioDynamics follow-on deals get off; bird flu vaccine names continue to climb
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/22/2006 | BT | Adventrx gets FDA clearance to start CoFactor phase 3 chemotherapy trial
|
5/22/2006 | BT | Adventrx pulls follow-on offering of 15.5 million shares due to adverse market climate
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/16/2006 | BT | Adventrx plans follow-on offering of 15.5 million shares via UBS
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/2/2006 | BT | Adventrx files $100 million stock shelf
|
4/26/2006 | BT | Adventrx: Preclinical results for Thiovir show antiviral activity against avian flu, herpes, HIV
|
4/10/2006 | BT | Adventrx to acquire SD Pharmaceuticals
|
4/5/2006 | BT | Adventrx says chemotherapy agent ANX-530 reduces vein irritation
|
4/3/2006 | BT | Adventrx: Preclinical data show strong antiviral synergy for Thiovir with zidovudine against HIV
|
3/20/2006 | BT | Adventrx says Thiovir active against H5N1 avian influenza chimeric virus strains
|
3/17/2006 | BT | Adventrx delays dosing in phase 3 CoFactor trial to await FDA response to request for protocol changes
|
2/14/2006 | BT | Adventrx says patient recruitment past halfway point in trial of CoFactor for cancer
|
1/31/2006 | BT | Adventrx says independent studies show Thiovir inhibits influenza A
|
1/30/2006 | BT | Adventrx: CoFactor shows 85% benefit against colorectal cancer in phase 2 trial
|
12/7/2005 | BT | Adventrx says FDA affirmed IND proposal for clinical trials of chemotheraphy agent ANX-530
|
12/7/2005 | BT | Adventrx terminates licensing of BlockAide/CR for HIV, cites "significant hurdles"
|
10/21/2005 | BT | Adventrx sees positive results using CoFactor against colorectal cancer
|
7/25/2005 | PP | Market Commentary: Volume remains light as stocks fall, oil makes meager gains; American Oil wraps $13.5 million offering
|
7/22/2005 | BT | Market Commentary: Momenta gains at open, then goes south; Adams up against market; Durect convertibles up on buyback
|
7/22/2005 | PP | Market Commentary: PIPE volume cools as week winds down; Adventrx raises $20 million in stock offering
|
7/22/2005 | BTPP | New Issue: Adventrx Pharmaceuticals secures $20 million in stock offering
|